Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 W ELECTROLYTES versus AMINOSYN II 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 7 W ELECTROLYTES versus AMINOSYN II 7.
AMINOSYN 7% W/ ELECTROLYTES vs AMINOSYN II 7%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids are the building blocks for protein synthesis in the body. This solution provides essential and non-essential amino acids to maintain nitrogen balance and support tissue repair and growth when oral intake is inadequate.
Aminosyn II 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for protein synthesis and supports metabolic functions in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion at 1-1.5 g amino acids/kg/day. Typical adult dose: 500 mL of 7% solution (35 g amino acids) infused over 8-12 hours, repeated daily as per nitrogen requirements.
Intravenous infusion; typical adult dose: 0.8-1.5 g amino acids/kg/day (11.4-21.4 mL/kg/day of 7% solution); rate not exceeding 0.1 g amino acids/kg/hour.
None Documented
None Documented
Terminal elimination half-life for the constituent amino acids ranges from 0.5 to 4 hours, depending on the specific amino acid and metabolic state. Clinically, infusion rate should be adjusted to avoid accumulation in renal impairment.
Not applicable; exogenous amino acids are rapidly cleared from plasma with a terminal half-life of 15-20 minutes for individual amino acids.
Primarily renal. Amino acids are deaminated, and nitrogen is excreted as urea in urine. Biliary/fecal excretion is negligible. Almost 100% of infused amino acids are either metabolized or excreted as urea and other nitrogenous wastes.
Renal as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution